Biotech News

New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits

Progyny (PGNY)Progyny2026-10-28 13:52 ESTCompany update

Research presented at ASRM 2026 Scientific Congress & Expo highlights the importance of early engagement and personalized support in helping patients navigate fertility care NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family

Related news

PGNYProgyny2026-04-16 13:06 EST

Progyny Expands Access to Fertility and Women’s Health with Industry’s First Fully Insured Supplemental Plan

PGNYProgyny2025-11-20 14:23 EST

New Men’s Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action

FEMYFEMASYS2026-09-09 13:00 EST

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

FEMYFEMASYS2026-05-05 13:00 EST

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

DAREDare Bioscience, Inc.2019-09-11 12:00 EST

Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics

MGRXMANGOCEUTICALS2025-02-03 13:30 EST

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

MGRXMANGOCEUTICALS2026-02-19 21:05 EST

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

View all latest news

Progyny

Women's Health and Family Building Progyny manages employer-sponsored benefits for fertility, family building and women's health. Its programs are designed to guide members through complex care while helping benefit purchasers manage quality and cost. Integrated Benefit Platform The company's services include fertility treatment,...

Recent company news

PGNYProgyny2026-11-04 21:01 EST

Progyny, Inc. Announces Third Quarter 2026 Results

PGNYProgyny2026-10-28 13:52 EST

New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits

PGNYProgyny2026-10-26 15:25 EST

New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model

PGNYProgyny2026-10-21 14:43 EST

Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report

PGNYProgyny2026-10-15 13:35 EST

Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting

Stock data

Close: 34.37 USD
Market cap: 1.97B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States